公开(公告)号：US20230036793A1

公开(公告)日：2023-02-02

申请号：US17784492

申请日：2020-12-11

Applicant: ILTOO PHARMA ,  SORBONNE UNIVERSITE ,  INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MEDICALE) ,  ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS

Inventor： David KLATZMANN ,  Nicolas BILLIALD ,  Thomas VAZQUEZ ,  Jérémie MARIAU

IPC: C07K14/55 ,  C07K14/47 ,  A61P37/06

Abstract: The present invention relates to a chimeric construct, comprising i) an interleukin 2 (IL2) moiety and ii) a beta chain of the C4b-binding protein (C4BPβ) or at least one fragment or functional variant thereof that is capable of forming a dimeric protein.

公开(公告)号：US11534479B2

公开(公告)日：2022-12-27

申请号：US16965700

申请日：2019-02-18

Applicant: ILTOO PHARMA ,  ASSISTANCE PUBLIQUE—HÔPITAUX DE PARIS ,  SORBONNE UNIVERSITÉ

Inventor： David Klatzmann ,  Roberta Lorenzon ,  Michèle Rosenzwajg ,  Patrice Cacoub ,  Arsene Mekinian

IPC: A61K38/20 ,  A61K47/68 ,  A61K47/60 ,  A61P37/00

Abstract: The invention relates to the use of interleukin-2 in treating Sjögren's syndrome in a subject, wherein IL-2 is to be administered at a low dose of less than about 3.5 MIU/day.

公开(公告)号：US11883531B2

公开(公告)日：2024-01-30

申请号：US16926881

申请日：2020-07-13

Applicant: ILTOO PHARMA

Inventor： Jérémie Mariau ,  Michel Thiry

IPC: A61K38/20 ,  A61K9/19 ,  A61K9/08 ,  A61K9/00 ,  A61K47/20 ,  A61K47/00 ,  A61K47/02 ,  A61J1/05

CPC classification number: A61K9/08 ,  A61K9/0019 ,  A61K9/19 ,  A61K38/2013 ,  A61K47/00 ,  A61K47/02 ,  A61K47/20 ,  A61J1/05

Abstract: The invention relates to a liquid pharmaceutical composition of Il-2 and its use in the treatment of auto-immune and inflammatory disorders. Methods for preparing said composition and delivery devices filled with said composition are also described.

公开(公告)号：US20210236599A1

公开(公告)日：2021-08-05

申请号：US17268030

申请日：2019-08-13

Applicant: ILTOO PHARMA ,  SORBONNE UNIVERSITE ,  ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS ,  INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE)

Inventor： David Klatzmann ,  Jérémie Mariau ,  Paul-Gydéon Ritvo ,  Encarnita Mariotti-Ferrandiz ,  Thomas Vazquez ,  Nicolas Billiald

IPC: A61K38/20 ,  A61K38/17 ,  C07K16/24 ,  A61K47/62

Abstract: The present invention relates to a combination of i) interleukin-2 (IL-2) and ii) an interleukin 1 (IL-1) inhibitor, for use in treating an auto-immune and/or inflammatory disorder in a subject. It is also provided a pharmaceutical composition comprising interleukin-2 (IL-2) and an interleukin-1 (IL-1) inhibitor. The invention further provides a conjugate comprising IL-2 conjugated to an IL-1 inhibitor.

公开(公告)号：US20240376172A1

公开(公告)日：2024-11-14

申请号：US18698994

申请日：2022-10-06

Applicant: ILTOO PHARMA ,  SORBONNE UNIVERSITE ,  ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS ,  INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE)

Inventor： David KLATZMANN ,  Alain TEDGUI ,  Thomas VAZQUEZ ,  Nicolas BILLIALD

IPC: C07K14/55 ,  A61K38/00 ,  A61P29/00 ,  A61P37/06 ,  C07K14/47 ,  C07K16/44 ,  C12N15/86

Abstract: The present invention relates to a targeted chimeric construct, comprising i) an interleukin 2 (IL2) moiety and ii) a targeting moiety which binds to an oxidized protein or oxidized lipid. The targeting moiety is preferably an antibody or scFv binding specific oxidized proteins or oxidized lipids and targets the fusion protein to inflammatory tissues. The chimeric construct preferably further comprises a beta chain of the C4b-binding protein (C4BP), which is capable of forming a dimeric protein.

公开(公告)号：US20210121532A1

公开(公告)日：2021-04-29

申请号：US16965700

申请日：2019-02-18

Applicant: ILTOO PHARMA ,  ASSISTANCE PUBLIQUE - HÖPITAUX DE PARIS ,  SORBONNE UNIVERSITÉ

Inventor： David KLATZMANN ,  Roberta LORENZON ,  Michèle ROSENZWAJG ,  Patrice CACOUB ,  Arsene MEKINIAN

IPC: A61K38/20 ,  A61P37/00 ,  A61K47/60 ,  A61K47/68

Abstract: The invention relates to the use of interleukin-2 in treating Sjögren's syndrome in a subject, wherein IL-2 is to be administered at a low dose of less than about 3.5 MIU/day.

公开(公告)号：US20180303754A1

公开(公告)日：2018-10-25

申请号：US15770066

申请日：2016-10-20

Applicant: ILTOO PHARMA

Inventor： Jérémie MARIAU ,  Michel THIRY

IPC: A61K9/08 ,  A61K38/20 ,  A61K9/00 ,  A61K47/20 ,  A61K47/02

Abstract: The invention relates to a liquid pharmaceutical composition of I1-2 and its use in the treatment of auto-immune and inflammatory disorders. Methods for preparing said composition and delivery devices filled with said composition are also described.

公开(公告)号：US20210128465A1

公开(公告)日：2021-05-06

申请号：US16926881

申请日：2020-07-13

Applicant: ILTOO PHARMA

Inventor： Jérémie MARIAU ,  Michel THIRY

IPC: A61K9/08 ,  A61K38/20 ,  A61K9/00 ,  A61K47/20 ,  A61K9/19 ,  A61K47/00 ,  A61K47/02

Abstract: The invention relates to a liquid pharmaceutical composition of Il-2 and its use in the treatment of auto-immune and inflammatory disorders. Methods for preparing said composition and delivery devices filled with said composition are also described.

公开(公告)号：US10722460B2

公开(公告)日：2020-07-28

申请号：US15770066

申请日：2016-10-20

Applicant: ILTOO PHARMA

Inventor： Jérémie Mariau ,  Michel Thiry

IPC: A61K38/20 ,  A61K9/08 ,  A61K9/00 ,  A61K47/20 ,  A61K9/19 ,  A61K47/00 ,  A61K47/02 ,  A61J1/05

Abstract: The invention relates to a liquid pharmaceutical composition of Il-2 and its use in the treatment of auto-immune and inflammatory disorders. Methods for preparing said composition and delivery devices filled with said composition are also described.

公开(公告)号：US20190060407A1

公开(公告)日：2019-02-28

申请号：US15758800

申请日：2016-09-09

Applicant: Assistance Publique - Hôpitaux De Paris ,  ILTOO PHARMA ,  SORBONNE UNIVERSITE

Inventor： David Klatzmann ,  Francis Berenbaum ,  Jérémie Sellam ,  Bruno Fautrel ,  Roberta Lorenzon ,  Patrice Cacoub

IPC: A61K38/20 ,  A61P19/02

Abstract: The invention relates to the use of interleukin-2 in treating spondyloarthritis in a human subject, wherein IL-2 is to be administered at a dose of about I to about 2 MIU/day, wherein the treatment comprises at least a first course wherein interleukin-2 is administered once per day during at least 3 consecutive days, followed by a maintenance treatment after 1 to 4 weeks.